ATE161270T1 - Aufklärung und synthese von ausgewählten pentapeptiden - Google Patents

Aufklärung und synthese von ausgewählten pentapeptiden

Info

Publication number: ATE161270T1
Authority: AT; Austria
Prior art keywords: pentapeptides; dolastatin; chem; peptides; elucidation
Prior art date: 1993-01-26

Application number

AT94300495T

Other languages

English (en)

Inventor

George R Pettit

Jayaram K Srirangam

Original Assignee

Univ Arizona

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-26

Filing date

1994-01-24

Publication date

1998-01-15

1994-01-24 Application filed by Univ Arizona filed Critical Univ Arizona

1998-01-15 Application granted granted Critical

1998-01-15 Publication of ATE161270T1 publication Critical patent/ATE161270T1/de

Links

230000015572 biosynthetic process Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 abstract 2
OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 abstract 2
108010045524 dolastatin 10 Proteins 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
241000237373 Aplysia sp. Species 0.000 abstract 1
241000237378 Dolabella auricularia Species 0.000 abstract 1
230000000118 anti-neoplastic effect Effects 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229940041181 antineoplastic drug Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000008878 coupling Effects 0.000 abstract 1
238000010168 coupling process Methods 0.000 abstract 1
238000005859 coupling reaction Methods 0.000 abstract 1
230000009897 systematic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Crystallography & Structural Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT94300495T 1993-01-26 1994-01-24 Aufklärung und synthese von ausgewählten pentapeptiden ATE161270T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/009,296 US5780588A (en)	1993-01-26	1993-01-26	Elucidation and synthesis of selected pentapeptides

Publications (1)

Publication Number	Publication Date
ATE161270T1 true ATE161270T1 (de)	1998-01-15

Family

ID=21736778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94300495T ATE161270T1 (de)	1993-01-26	1994-01-24	Aufklärung und synthese von ausgewählten pentapeptiden

Country Status (6)

Country	Link
US (1)	US5780588A (de)
EP (1)	EP0612762B1 (de)
JP (1)	JPH08119990A (de)
AT (1)	ATE161270T1 (de)
CA (1)	CA2114156C (de)
DE (1)	DE69407322T2 (de)

Families Citing this family (774)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0731106B1 (de) *	1993-10-01	2004-11-17	Teikoku Hormone Mfg. Co., Ltd.	Dolastatin-derivate
US6686445B1 (en)	1997-09-24	2004-02-03	Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University	Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
ATE293638T1 (de) *	1997-09-24	2005-05-15	Univ Arizona	Synthetische antineoplastische wirkstoffe abgeleitet von dolastatin 15 sowie verfahren zu ihrer herstellung
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6884869B2 (en) *	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US7256257B2 (en) *	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
AU2002311919B8 (en)	2001-05-11	2007-03-22	Ludwig Institute For Cancer Research Ltd	Specific binding proteins and uses thereof
DK1545613T3 (da)	2002-07-31	2011-11-14	Seattle Genetics Inc	Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP5356648B2 (ja)	2003-02-20	2013-12-04	シアトルジェネティックス，インコーポレイテッド	抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
EP2478912B1 (de)	2003-11-06	2016-08-31	Seattle Genetics, Inc.	Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung
DK1791565T3 (en)	2004-09-23	2016-08-01	Genentech Inc	Cysteingensplejsede antibodies and conjugates
US8288352B2 (en) *	2004-11-12	2012-10-16	Seattle Genetics, Inc.	Auristatins having an aminobenzoic acid unit at the N terminus
DE602005022928D1 (de)	2004-11-30	2010-09-23	Abgenix Inc	Antikörper gegen gpnmb und ihre verwendungen
FR2883873B1 (fr)	2005-03-31	2009-07-10	Pharmamens Sarl	Inhibiteurs d'age
JP5122441B2 (ja)	2005-04-19	2013-01-16	シアトルジェネティックス，インコーポレイテッド	ヒト化抗ｃｄ７０結合剤およびその使用
ES2708763T3 (es)	2005-07-07	2019-04-11	Seattle Genetics Inc	Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en)	2005-07-07	2007-01-18	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
DK3248613T3 (da)	2005-07-18	2022-03-14	Seagen Inc	Beta-glucuronid-lægemiddel-linkerkonjugater
BRPI0619118A2 (pt)	2005-12-02	2011-09-13	Genentech Inc	composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
CA2633887C (en)	2005-12-15	2015-12-22	Genentech, Inc.	Methods and compositions for targeting polyubiquitin
BRPI0706840A2 (pt)	2006-01-05	2011-04-05	Genentech Inc	anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
SI1976884T1 (sl)	2006-01-20	2013-04-30	Genetech, Inc.	Anti-efrinB2 protitelesa in postopki uporabe le teh
US7750116B1 (en) *	2006-02-18	2010-07-06	Seattle Genetics, Inc.	Antibody drug conjugate metabolites
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
EP2032606B1 (de)	2006-05-30	2013-11-27	Genentech, Inc.	Antikörper und immunkonjugate sowie ihre verwendungen
US7910108B2 (en) *	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
ES2372217T3 (es)	2006-09-12	2012-01-17	Genentech, Inc.	Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
BRPI0717638A2 (pt)	2006-10-27	2013-11-12	Genentech Inc	Anticorpors e imunoconjugados e usos para os mesmos
PT2099823E (pt)	2006-12-01	2014-12-22	Seattle Genetics Inc	Agentes de ligação ao alvo variantes e suas utilizações
US9090693B2 (en)	2007-01-25	2015-07-28	Dana-Farber Cancer Institute	Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
MX2009008430A (es)	2007-02-09	2009-10-28	Genentech Inc	Anticuerpos anti-robo4 y sus usos.
CA2680854C (en)	2007-03-15	2017-02-14	Ludwig Institute For Cancer Research	Treatment method using egfr antibodies and src inhibitors and related formulations
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CL2008001334A1 (es)	2007-05-08	2008-09-22	Genentech Inc	Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PE20090943A1 (es)	2007-07-16	2009-08-05	Genentech Inc	Anticuerpos anti-cd79b e inmunoconjugados
EP2176295B1 (de)	2007-07-16	2014-11-19	Genentech, Inc.	Humanisierte anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
CN108424454B (zh)	2007-08-14	2022-05-31	路德维格癌症研究所有限公司	靶向egf受体的单克隆抗体175及其衍生物和用途
KR101680906B1 (ko)	2007-09-26	2016-11-30	추가이 세이야쿠 가부시키가이샤	항체 정상영역 개변체
CN102099055A (zh)	2007-10-04	2011-06-15	津莫吉尼蒂克斯公司	B7家族成员zB7H6及相关的组合物和方法
DK2211904T3 (en)	2007-10-19	2016-10-24	Seattle Genetics Inc	Cd19-binding agents and uses thereof
EP3115469B1 (de)	2007-11-19	2020-04-29	Celera Corporation	Lungenkrebsmarker und verwendungen davon
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
BRPI0907046A2 (pt)	2008-01-18	2015-07-28	Medimmune Llc	Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
KR101607346B1 (ko)	2008-01-31	2016-03-29	제넨테크, 인크.	항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
DK2265283T3 (da)	2008-03-18	2014-10-20	Seattle Genetics Inc	Auristatin-lægemiddel-linker-konjugater
BRPI0906261A2 (pt) *	2008-03-31	2015-07-07	Genentech Inc	"métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
SG10202112838YA (en)	2008-04-09	2021-12-30	Genentech Inc	Novel compositions and methods for the treatment of immune related diseases
WO2009135181A2 (en)	2008-05-02	2009-11-05	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
ES2442024T3 (es)	2008-07-15	2014-02-07	Academia Sinica	Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
AR073717A1 (es)	2008-10-01	2010-11-24	Genentech Inc	Anticuerpos anti-notch2 de murino y humano, y metodos de uso
UA109633C2 (uk)	2008-12-09	2015-09-25		Антитіло людини проти тканинного фактора
MY152068A (en)	2009-03-20	2014-08-15	Genentech Inc	Bispecific anti-her antibodies
MA33208B1 (fr)	2009-03-25	2012-04-02	Genentech Inc	Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
NZ594343A (en)	2009-03-25	2013-10-25	Genentech Inc	Novel anti-alpha5beta1 antibodies and uses thereof
RU2587621C2 (ru)	2009-04-01	2016-06-20	Дженентек, Инк.	АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2756244A1 (en)	2009-04-02	2010-10-07	Roche Glycart Ag	Multispecific antibodies comprising full length antibodies and single chain fab fragments
PE20120835A1 (es)	2009-04-16	2012-07-23	Abbvie Biotherapeutics Inc	Anticuerpos anti-tnf-alfa y sus usos
MX2011012665A (es)	2009-06-04	2012-03-07	Novartis Ag	Metodos para identificacion de sitios para conjugacion de igg.
EP2443150B1 (de)	2009-06-17	2015-01-21	AbbVie Biotherapeutics Inc.	Anti-vegf-antikörper und anwendungen davon
EP2711018A1 (de)	2009-06-22	2014-03-26	MedImmune, LLC	Manipulierte Fc-Regionen für standortspezifische Konjugation
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2772715C (en)	2009-09-02	2019-03-26	Genentech, Inc.	Mutant smoothened and methods of using the same
EP2478013B1 (de)	2009-09-16	2018-10-24	F.Hoffmann-La Roche Ag	Coiled-coil- und/oder tether-haltige proteinkomplexe und verwendungen davon
RU2559533C2 (ru)	2009-10-22	2015-08-10	Дженентек, Инк.	Антитела против гепсина и способы их применения
SG10201407757XA (en)	2009-10-23	2015-01-29	Millennium Pharm Inc	Anti-gcc antibody molecules and related compositions and methods
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
CA2777825A1 (en)	2009-10-28	2011-05-19	Abbott Biotherapeutics Corp.	Anti-egfr antibodies and their uses
EP2496601B1 (de)	2009-11-05	2017-06-07	F. Hoffmann-La Roche AG	Methoden und zusammensetzung zur sekretion heterologer polypeptide
PH12012500982A1 (en)	2009-11-30	2019-07-10	Genentech Inc	Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
CN102770456B (zh)	2009-12-04	2018-04-06	弗·哈夫曼-拉罗切有限公司	多特异性抗体、抗体类似物、组合物和方法
EA024629B1 (ru)	2009-12-09	2016-10-31	Институт Насьональ Де Ла Сант Де Ла Решерше Медикаль	Моноклональные антитела, связывающие b7h6, и их применение
ES2722300T3 (es) *	2009-12-10	2019-08-09	Hoffmann La Roche	Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
WO2011071577A1 (en)	2009-12-11	2011-06-16	Genentech, Inc.	Anti-vegf-c antibodies and methods using same
EP2513148B1 (de)	2009-12-16	2016-08-31	AbbVie Biotherapeutics Inc.	Anti-her2-antikörper und ihre verwendung
EP2516465B1 (de)	2009-12-23	2016-05-18	F.Hoffmann-La Roche Ag	Anti-bv8 antikörper und deren verwendungen
CN102844045A (zh)	2010-02-08	2012-12-26	艾更斯司股份有限公司	结合于161p2f10b蛋白的抗体药物偶联物(adc)
US9556249B2 (en)	2010-02-18	2017-01-31	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
MA34057B1 (fr)	2010-02-23	2013-03-05	Genentech Inc	Compositions et methodes pour le diagnostic et le traitement d'une tumeur
US9169323B2 (en)	2010-03-05	2015-10-27	Hoffmann-La Roche Inc.	Antibodies against human CSF-1R
JP5989547B2 (ja)	2010-03-05	2016-09-07	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	ヒトｃｓｆ−１ｒに対する抗体及びその使用
CN106432474A (zh)	2010-03-12	2017-02-22	艾伯维生物医疗股份有限公司	Ctla4蛋白和其用途
AR080795A1 (es)	2010-03-24	2012-05-09	Genentech Inc	Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
HUE049849T2 (hu)	2010-03-31	2020-10-28	Boehringer Ingelheim Int	Anti-CD40 antitestek
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
KR101860963B1 (ko)	2010-04-23	2018-05-24	제넨테크, 인크.	이종다량체 단백질의 생산
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
NZ701208A (en)	2010-06-03	2016-05-27	Genentech Inc	Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
CA2799540A1 (en)	2010-06-08	2011-12-15	Genentech, Inc.	Cysteine engineered antibodies and conjugates
SMT202000031T1 (it)	2010-06-09	2020-03-13	Genmab As	Anticorpi contro cd38 umano
BR112012031727B1 (pt)	2010-06-15	2022-03-29	Genmab A/S	Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
RU2577986C2 (ru)	2010-06-18	2016-03-20	Дженентек, Инк.	Антитела против axl и способы их применения
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
AU2011283694B2 (en)	2010-07-29	2017-04-13	Xencor, Inc.	Antibodies with modified isoelectric points
KR20130045914A (ko)	2010-08-03	2013-05-06	에프. 호프만-라 로슈 아게	만성 림프구성 백혈병(cll) 생체지표
CA2806021C (en)	2010-08-13	2019-05-21	Roche Glycart Ag	Anti-fap antibodies and methods of use
EP2603529A1 (de)	2010-08-13	2013-06-19	Roche Glycart AG	Anti-tenascin-c-a2-antikörper und verwendungsverfahren dafür
CA2808185A1 (en)	2010-08-13	2012-02-16	Genentech, Inc.	Antibodies to il-1.beta. and il-18, for treatment of disease
CN103068846B9 (zh)	2010-08-24	2016-09-28	弗·哈夫曼-拉罗切有限公司	包含二硫键稳定性Fv片段的双特异性抗体
MX2013002084A (es)	2010-08-31	2013-05-09	Genentech Inc	Biomarcadores y metodos de tratamiento.
MX347954B (es)	2010-09-29	2017-05-19	Agensys Inc	Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
EP3828205A1 (de)	2010-10-01	2021-06-02	Oxford BioTherapeutics Ltd	Anti-ror1-antikörper
DK2625197T3 (en)	2010-10-05	2016-10-03	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
EP3581206B8 (de)	2010-10-22	2025-02-19	Seagen Inc.	Synergiewirkung zwischen auristatin-basierten antikörper-wirkstoffkonjugaten und hemmern des pi3k-akt-mtor-wegs
WO2012064836A1 (en)	2010-11-10	2012-05-18	Genentech, Inc.	Methods and compositions for neural disease immunotherapy
EP2637692A4 (de)	2010-11-12	2014-09-10	Scott & White Healthcare	Antikörper gegen den endothelialen tumormarker 8
RU2578468C2 (ru)	2010-12-16	2016-03-27	Дженентек, Инк.	Способы диагностики и лечения, связанные с ингибированием th2
BR112013014527A2 (pt)	2010-12-20	2017-03-07	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
CN103261230A (zh)	2010-12-22	2013-08-21	霍夫曼-拉罗奇有限公司	抗pcsk9抗体及使用方法
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
RU2018108836A (ru)	2011-02-04	2019-03-14	Дженентек, Инк.	ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
EP2673297A2 (de)	2011-02-11	2013-12-18	Zyngenia, Inc.	Monovalente und multivalente multispezifische komplexe und verwendungen davon
ES2692268T5 (en)	2011-03-29	2025-02-26	Roche Glycart Ag	Antibody fc variants
CA2828890A1 (en)	2011-04-07	2012-10-11	Genentech, Inc.	Anti-fgfr4 antibodies and methods of use
CN103796678B (zh)	2011-04-20	2018-02-27	健玛保	针对her2的双特异性抗体
RU2013150331A (ru)	2011-04-20	2015-05-27	Рош Гликарт Аг	СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
EP4520771A3 (de)	2011-04-20	2025-07-16	Genmab A/S	Bispezifische antikörper gegen her2
SG194735A1 (en)	2011-05-09	2013-12-30	Univ Virginia Patent Found	Compositions and methods for treating cancer
US8679767B2 (en)	2011-05-12	2014-03-25	Genentech, Inc.	Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
EA030462B1 (ru)	2011-05-16	2018-08-31	Дженентек, Инк.	Агонисты fgfr1 и способы их применения
CA2836338C (en)	2011-05-16	2022-05-03	Koninklijke Philips N.V.	Tetrazine derivatives used in bio-orthogonal drug activation
JP2014516960A (ja)	2011-05-19	2014-07-17	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	抗ヒトｈｅｒ３抗体及びその使用
EP2714738B1 (de)	2011-05-24	2018-10-10	Zyngenia, Inc.	Multivalente und monovalente multispezifische komplexe und ihre verwendungen
KR101972446B1 (ko)	2011-05-27	2019-04-25	글락소 그룹 리미티드	Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
WO2012171020A1 (en)	2011-06-10	2012-12-13	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
CA2839508A1 (en)	2011-06-22	2012-12-27	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-axl antibodies and uses thereof
ES2677367T3 (es)	2011-06-22	2018-08-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticuerpos anti-Axl y usos de los mismos
AR086823A1 (es)	2011-06-30	2014-01-22	Genentech Inc	Formulaciones de anticuerpo anti-c-met, metodos
UA117901C2 (uk)	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
MX2014001766A (es)	2011-08-17	2014-05-01	Genentech Inc	Anticuerpos de neuregulina y sus usos.
JP6060162B2 (ja)	2011-08-23	2017-01-11	ロシュグリクアートアーゲー	２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
WO2013026839A1 (en)	2011-08-23	2013-02-28	Roche Glycart Ag	Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2013040433A1 (en)	2011-09-15	2013-03-21	Genentech, Inc.	Methods of promoting differentiation
SG11201400724SA (en)	2011-09-19	2014-04-28	Genentech Inc	Combination treatments comprising c-met antagonists and b-raf antagonists
JP6041882B2 (ja)	2011-09-23	2016-12-14	ロシュグリクアートアーゲー	二重特異性抗ｅｇｆｒ／抗ｉｇｆ−１ｒ抗体
CN108152513B (zh)	2011-09-29	2020-07-24	西雅图基因公司	蛋白偶联的试剂化合物的整体分子量测定
US9663573B2 (en)	2011-10-05	2017-05-30	Genentech, Inc.	Methods of treating liver conditions using Notch2 antagonists
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2012323287B2 (en)	2011-10-10	2018-02-01	Xencor, Inc.	A method for purifying antibodies
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP6134725B2 (ja)	2011-10-14	2017-05-24	ジェネンテック，インコーポレイテッド	Ｂａｃｅ１のペプチド阻害剤
BR112014008862A2 (pt)	2011-10-14	2018-08-07	Genentech Inc	anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
US9358250B2 (en)	2011-10-15	2016-06-07	Genentech, Inc.	Methods of using SCD1 antagonists
MX2014004991A (es)	2011-10-28	2014-05-22	Genentech Inc	Combinaciones terapeuticas y metodos para tratar el melanoma.
SG11201402485UA (en)	2011-11-21	2014-06-27	Genentech Inc	Purification of anti-c-met antibodies
RU2658603C2 (ru)	2011-12-15	2018-06-21	Ф.Хоффманн-Ля Рош Аг	Антитела против человеческого csf-1r и их применения
JP2015502397A (ja)	2011-12-23	2015-01-22	ファイザー・インク	部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP2015509091A (ja)	2012-01-09	2015-03-26	ザスクリプスリサーチインスティテュート	ヒト化抗体
CA2863224A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
US9200072B2 (en)	2012-01-18	2015-12-01	Genentech Inc.	Anti-LRP5 antibodies and methods of use
JP2015506944A (ja)	2012-01-18	2015-03-05	ジェネンテック，インコーポレイテッド	Ｆｇｆ１９修飾薬を使用する方法
WO2013109994A1 (en)	2012-01-20	2013-07-25	Sea Lane Biotechnologies, Llc	Surrobody cojugates
CA2861124A1 (en)	2012-02-10	2013-08-15	Genentech, Inc.	Single-chain antibodies and other heteromultimers
KR102148303B1 (ko)	2012-02-11	2020-08-26	제넨테크, 인크.	R-스폰딘 전위 및 그의 사용 방법
MX360352B (es)	2012-02-15	2018-10-30	Hoffmann La Roche	Cromatografia de afinidad basada en receptores fc.
WO2013130093A1 (en)	2012-03-02	2013-09-06	Genentech, Inc.	Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9156915B2 (en)	2012-04-26	2015-10-13	Thomas Jefferson University	Anti-GCC antibody molecules
US9056910B2 (en)	2012-05-01	2015-06-16	Genentech, Inc.	Anti-PMEL17 antibodies and immunoconjugates
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
CN104640572B (zh) *	2012-05-15	2018-04-27	索伦托医疗有限公司	药物偶联物，偶联方法，及其用途
US9522940B2 (en)	2012-05-23	2016-12-20	Pieris Pharmaceuticals Gmbh	Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
EP2859017B1 (de)	2012-06-08	2019-02-20	Sutro Biopharma, Inc.	Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
EP2861624A1 (de)	2012-06-15	2015-04-22	F. Hoffmann-La Roche AG	Anti-pcsk9-antikörper, formulierungen, dosierung und verfahren zur verwendung
KR102190832B1 (ko)	2012-06-19	2020-12-15	암브룩스, 인코포레이티드	항cd70 항체 약물 컨쥬게이트
WO2014004639A1 (en)	2012-06-26	2014-01-03	Sutro Biopharma, Inc.	Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
KR20150030744A (ko)	2012-06-27	2015-03-20	에프. 호프만-라 로슈 아게	표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
WO2014001326A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
RU2684595C2 (ru)	2012-07-04	2019-04-09	Ф.Хоффманн-Ля Рош Аг	Ковалентно связанные конъюгаты антиген-антитело
EP2870180B1 (de)	2012-07-04	2024-08-28	F. Hoffmann-La Roche AG	Anti-biotin-antikörper und verwendungsverfahren
DK2869837T3 (en)	2012-07-04	2016-09-26	Hoffmann La Roche	Anti-theophylline antibodies and methods of use
EP3632462A1 (de)	2012-07-06	2020-04-08	Genmab B.V.	Dimerprotein mit dreifacher mutation
CN104736174B (zh)	2012-07-06	2019-06-14	根马布私人有限公司	具有三重突变的二聚体蛋白质
SG11201408538PA (en)	2012-07-13	2015-02-27	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
TWI606063B (zh)	2012-08-23	2017-11-21	艾澤西公司	結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
EP2890402B1 (de)	2012-08-31	2019-04-17	Sutro Biopharma, Inc.	Modifizierte aminosäuren mit einer azidogruppe
KR20150056788A (ko)	2012-09-19	2015-05-27	애브비 바이오테라퓨틱스 인크.	면역원성이 감소된 항체의 동정 방법
RU2015117393A (ru)	2012-10-08	2016-12-10	Роше Гликарт Аг	Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
WO2014068079A1 (en)	2012-11-01	2014-05-08	Max-Delbrück-Centrum für Molekulare Medizin	An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
MA38165A1 (fr)	2012-11-08	2018-07-31	Hoffmann La Roche	Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
CN104968367B (zh)	2012-11-13	2018-04-13	弗·哈夫曼-拉罗切有限公司	抗血凝素抗体和使用方法
FI2922574T3 (fi)	2012-11-22	2023-08-11	Tagworks Pharmaceuticals B V	Kemiallisesti pilkkoutuva ryhmä
CA2891280C (en)	2012-11-24	2018-03-20	Hangzhou Dac Biotech Co., Ltd.	Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US20140154255A1 (en)	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
CA2892863C (en)	2012-12-10	2022-03-15	Mersana Therapeutics, Inc.	Polymeric scaffold based on phf for targeted drug delivery
WO2014093379A1 (en)	2012-12-10	2014-06-19	Mersana Therapeutics, Inc.	Auristatin compounds and conjugates thereof
WO2014093640A1 (en)	2012-12-12	2014-06-19	Mersana Therapeutics,Inc.	Hydroxy-polmer-drug-protein conjugates
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
KR20200024345A (ko)	2013-01-10	2020-03-06	젠맵 비. 브이	인간 IgG1 Fc 영역 변이체 및 그의 용도
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
KR102211837B1 (ko)	2013-01-14	2021-02-03	젠코어 인코포레이티드	신규한 이형이량체 단백질
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
WO2014113510A1 (en)	2013-01-15	2014-07-24	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
US20140242083A1 (en)	2013-02-26	2014-08-28	Roche Glycart Ag	Anti-mcsp antibodies
MX2015011428A (es)	2013-03-06	2016-02-03	Genentech Inc	Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
JP6436965B2 (ja)	2013-03-14	2018-12-12	ジェネンテック，インコーポレイテッド	抗ｂ７−ｈ４抗体及びイムノコンジュゲート
JP2016516046A (ja)	2013-03-14	2016-06-02	ジェネンテック，インコーポレイテッド	がんの治療方法及びがん薬物耐性を阻止する方法
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
HK1220470A1 (zh)	2013-03-15	2017-05-05	Abbvie Biotechnology Ltd.	抗cd25抗体及其用途
HK1220626A1 (zh)	2013-03-15	2017-05-12	The Centre For Drug Research And Development	具细胞毒性和抗有丝分裂的化合物以及其使用方法
WO2014150877A2 (en)	2013-03-15	2014-09-25	Ac Immune S.A.	Anti-tau antibodies and methods of use
SG11201507427QA (en)	2013-03-15	2015-10-29	Genentech Inc	Compositions and methods for diagnosis and treatment of hepatic cancers
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10150800B2 (en)	2013-03-15	2018-12-11	Zyngenia, Inc.	EGFR-binding modular recognition domains
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
MX2015012549A (es)	2013-03-15	2016-06-21	Abbvie Deutschland	Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
CA2905123A1 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
KR20150131177A (ko)	2013-03-15	2015-11-24	제넨테크, 인크.	항-CRTh2 항체 및 그의 용도
MX2015012563A (es)	2013-03-15	2016-10-26	Abbvie Biotechnology Ltd	Anticuerpos anti-cd25 y sus usos.
EP2970486B1 (de)	2013-03-15	2018-05-16	Xencor, Inc.	Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
BR112015023120A2 (pt)	2013-03-15	2017-11-21	Genentech Inc	método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
JP6594855B2 (ja)	2013-03-15	2019-10-23	ゼンコアインコーポレイテッド	ヘテロ二量体タンパク質
EP2968589A1 (de)	2013-03-15	2016-01-20	AbbVie Inc.	Aufreinigung eins antikörper-wirkstoff-konjugats (adc)
US20140377253A1 (en)	2013-03-15	2014-12-25	Abbvie Biotherapeutics Inc.	Fc variants
AR095882A1 (es)	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB2513405A (en)	2013-04-26	2014-10-29	Adc Biotechnology Ltd	Method of synthesising ADCs using affinity resins
WO2014177459A2 (en)	2013-04-29	2014-11-06	F. Hoffmann-La Roche Ag	Fc-receptor binding modified asymmetric antibodies and methods of use
EP3594240B1 (de)	2013-05-20	2023-12-06	F. Hoffmann-La Roche AG	Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
EP3013365B1 (de)	2013-06-26	2019-06-05	Academia Sinica	Rm2-antigene und verwendung davon
EP3013347B1 (de)	2013-06-27	2019-12-11	Academia Sinica	Glykankonjugate und verwendung davon
WO2015006555A2 (en)	2013-07-10	2015-01-15	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015017146A2 (en)	2013-07-18	2015-02-05	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CA2918370A1 (en)	2013-07-18	2015-01-22	Fabrus, Inc.	Humanized antibodies with ultralong complementarity determining regions
EP3738611B1 (de)	2013-07-31	2025-09-03	BioNTech SE	Diagnose und therapie von krebs mit krebsstammzellen
WO2015017552A1 (en)	2013-08-01	2015-02-05	Agensys, Inc.	Antibody drug conjugates (adc) that bind to cd37 proteins
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
JP6486368B2 (ja)	2013-09-06	2019-03-20	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP6282745B2 (ja)	2013-09-12	2018-02-21	ハロザイムインコーポレイテッド	修飾抗上皮成長因子受容体抗体およびその使用法
JP2016537399A (ja)	2013-09-17	2016-12-01	ジェネンテック，インコーポレイテッド	抗ｌｇｒ５抗体を使用する方法
CN105813654B (zh)	2013-10-11	2019-05-31	美国政府(由卫生和人类服务部的部长所代表)	Tem8抗体及其用途
ES2754397T3 (es)	2013-10-11	2020-04-17	Asana Biosciences Llc	Conjugados de proteína-polímero-fármaco
CN105745224B (zh)	2013-10-11	2019-11-05	牛津生物疗法有限公司	用于治疗癌症的针对ly75的偶联抗体
KR102087850B1 (ko)	2013-10-11	2020-03-12	메르사나 테라퓨틱스, 인코포레이티드	단백질-고분자-약물 접합체
EP3055298B1 (de)	2013-10-11	2020-04-29	Sutro Biopharma, Inc.	Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
AU2014337317A1 (en)	2013-10-15	2016-09-15	Sorrento Therapeutics Inc.	Drug-conjugates with a targeting molecule and two different drugs
US9644037B2 (en)	2013-10-18	2017-05-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
BR112016008477A2 (pt)	2013-10-18	2017-10-03	Genentech Inc	Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
WO2015069922A2 (en)	2013-11-06	2015-05-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN105849125B (zh)	2013-11-07	2020-05-15	国家医疗保健研究所	神经调节蛋白变构抗her3抗体
SI3071237T1 (sl)	2013-11-21	2024-11-29	Genmab A/S	Liofilizirana formulacija konjugata protitelo-zdravilo
SG11201604784XA (en)	2013-12-13	2016-07-28	Genentech Inc	Anti-cd33 antibodies and immunoconjugates
TWI670283B (zh)	2013-12-23	2019-09-01	美商建南德克公司	抗體及使用方法
WO2015095953A1 (en)	2013-12-27	2015-07-02	The Centre For Drug Research And Development	Sulfonamide-containing linkage systems for drug conjugates
BR112016015105A8 (pt)	2013-12-27	2018-04-24	Var2 Pharmaceuticals Aps	conjugados var2csa-droga
BR112016014945A2 (pt)	2014-01-03	2018-01-23	F. Hoffmann-La Roche Ag	conjugado, formulação farmacêutica e uso
CN105899540B (zh)	2014-01-03	2020-02-07	豪夫迈·罗氏有限公司	双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用
WO2015103549A1 (en)	2014-01-03	2015-07-09	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
EP3089758B1 (de)	2014-01-03	2021-01-27	F.Hoffmann-La Roche Ag	Kovalent verknüpfte helikar-/anti-helikar-antikörperkonjugate und verwendungen davon
AU2015206515B2 (en)	2014-01-15	2019-12-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cartilage targeting agents and their use
AU2015206370A1 (en)	2014-01-16	2016-07-07	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
EP3096797A1 (de)	2014-01-24	2016-11-30	F. Hoffmann-La Roche AG	Verfahren zur verwendung von anti-steap1-antikörpern und immunkonjugaten
ES2694857T3 (es)	2014-02-04	2018-12-27	Genentech, Inc.	Smoothened mutante y métodos de uso de la misma
EA201691610A8 (ru)	2014-02-12	2018-05-31	Дженентек, Инк.	Анти-jagged1 антитела и способы применения
UA117608C2 (uk)	2014-02-21	2018-08-27	Дженентек, Інк.	Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
US10464955B2 (en)	2014-02-28	2019-11-05	Hangzhou Dac Biotech Co., Ltd.	Charged linkers and their uses for conjugation
AU2015229035B2 (en)	2014-03-14	2021-08-05	Genentech, Inc.	Methods and compositions for secretion of heterologous polypeptides
AR099812A1 (es)	2014-03-21	2016-08-17	Abbvie Inc	Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
CN106103478B (zh)	2014-03-21	2020-04-03	豪夫迈·罗氏有限公司	抗体体内半寿期的体外预测
RU2016141385A (ru)	2014-03-24	2018-04-28	Дженентек, Инк.	Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
CN106415244B (zh)	2014-03-27	2020-04-24	中央研究院	反应性标记化合物及其用途
EP3699195A3 (de)	2014-03-28	2020-11-04	Xencor, Inc.	Bispezifische, an cd38 und cd3 bindende antikörper
SG11201607969XA (en)	2014-03-31	2016-10-28	Genentech Inc	Anti-ox40 antibodies and methods of use
KR20160146747A (ko)	2014-03-31	2016-12-21	제넨테크, 인크.	항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
SG11201608192SA (en)	2014-04-11	2016-10-28	Medimmune Llc	Bispecific her2 antibodies
FR3020063A1 (fr)	2014-04-16	2015-10-23	Gamamabs Pharma	Anticorps humain anti-her4
BR122021009041B1 (pt)	2014-05-06	2022-11-29	Genentech, Inc	Métodos para a preparação de uma proteína heteromultimérica
RU2016144405A (ru)	2014-05-23	2018-06-26	Дженентек, Инк.	MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP7093612B2 (ja)	2014-05-27	2022-06-30	アカデミアシニカ	Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661099A (zh)	2014-05-27	2017-05-10	中央研究院	抗her2醣抗体及其用途
CA2950415A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
WO2015183978A1 (en)	2014-05-28	2015-12-03	Agensys, Inc.	Derivatives of dolaproine-dolaisoleuine peptides
WO2015184001A1 (en)	2014-05-28	2015-12-03	Academia Sinica	Anti-tnf-alpha glycoantibodies and uses thereof
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
BR112016029935A2 (pt)	2014-06-26	2017-10-31	Hoffmann La Roche	?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
SMT202000265T1 (it)	2014-07-11	2020-07-08	Genmab As	Anticorpi che legano axl
CN106488775A (zh)	2014-07-11	2017-03-08	基因泰克公司	Notch途径抑制
EP3194449A1 (de)	2014-07-24	2017-07-26	Xencor, Inc.	Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
JP6811706B2 (ja)	2014-07-31	2021-01-13	ザホンコンユニヴァーシティオブサイエンスアンドテクノロジー	Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
DK4074735T3 (da)	2014-08-28	2025-07-14	Bioatla Inc	Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
TWI751102B (zh)	2014-08-28	2022-01-01	美商奇諾治療有限公司	對ｃｄ１９具專一性之抗體及嵌合抗原受體
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
SG11201701128YA (en)	2014-09-12	2017-03-30	Genentech Inc	Cysteine engineered antibodies and conjugates
WO2016040724A1 (en)	2014-09-12	2016-03-17	Genentech, Inc.	Anti-b7-h4 antibodies and immunoconjugates
MA40579A (fr)	2014-09-12	2016-03-17	Genentech Inc	Anticorps anti-cll-1 et immunoconjugués
LT3191135T (lt)	2014-09-12	2020-11-25	Genentech, Inc.	Anti-her2 antikūnai ir imunokonjugatai
ES2905569T3 (es)	2014-09-17	2022-04-11	Zymeworks Inc	Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
HUE049175T2 (hu)	2014-09-23	2020-09-28	Hoffmann La Roche	Eljárás anti-CD79b immunkonjugátumok alkalmazására
RU2715905C2 (ru)	2014-10-01	2020-03-04	МЕДИММЬЮН, ЭлЭлСи	Способ конъюгации полипептида
JP2017536102A (ja)	2014-10-16	2017-12-07	ジェネンテック，インコーポレイテッド	抗アルファ−シヌクレイン抗体及び使用方法
GB201419185D0 (en)	2014-10-28	2014-12-10	Adc Biotechnology Ltd	Method of synthesising ADCs using affinity resin
WO2016070062A2 (en)	2014-10-31	2016-05-06	Genentech, Inc.	Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
WO2016073380A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
CA2966523A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Assays for detecting t cell immune subsets and methods of use thereof
CA2961439A1 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Anti-fgfr2/3 antibodies and methods using same
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
DK3215528T3 (da)	2014-11-06	2019-10-07	Hoffmann La Roche	Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
CR20170240A (es)	2014-11-10	2018-04-03	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos
JP6859259B2 (ja)	2014-11-19	2021-04-14	ジェネンテック，インコーポレイテッド	ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
WO2016081640A1 (en)	2014-11-19	2016-05-26	Genentech, Inc.	Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US10508151B2 (en)	2014-11-19	2019-12-17	Genentech, Inc.	Anti-transferrin receptor antibodies and methods of use
EP3223907A2 (de)	2014-11-26	2017-10-04	Xencor, Inc.	Cd3 und cd38 bindende heterodimere antikörper
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171324A1 (es)	2014-11-26	2017-09-11	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
EP3227332B1 (de)	2014-12-03	2019-11-06	F.Hoffmann-La Roche Ag	Multispezifische antikörper
ES2744540T3 (es)	2014-12-05	2020-02-25	Hoffmann La Roche	Anticuerpos anti-CD79b y procedimientos de uso
JP6864953B2 (ja)	2014-12-09	2021-04-28	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ａｘｌに対するヒトモノクローナル抗体
KR20170085595A (ko)	2014-12-10	2017-07-24	제넨테크, 인크.	혈뇌 장벽 수용체 항체 및 사용 방법
BR112017011235A2 (pt)	2014-12-19	2018-02-06	Chugai Pharmaceutical Co Ltd	anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko)	2014-12-19	2018-05-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2016105450A2 (en)	2014-12-22	2016-06-30	Xencor, Inc.	Trispecific antibodies
ES2818103T3 (es)	2015-01-16	2021-04-09	Juno Therapeutics Inc	Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
CN113956354A (zh)	2015-01-22	2022-01-21	中外制药株式会社	两种以上抗-c5抗体的组合与使用方法
AU2016209056B2 (en)	2015-01-24	2021-01-28	Academia Sinica	Cancer markers and methods of use thereof
JP6779887B2 (ja)	2015-01-24	2020-11-04	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	新規なグリカンコンジュゲートおよびその使用方法
EP3250238B1 (de)	2015-01-28	2022-06-01	Sorrento Therapeutics, Inc.	Antikörper-wirkstoff-konjugate
EP3253784B1 (de)	2015-02-04	2020-05-06	Genentech, Inc.	Smoothened-mutant und verfahren zur verwendung davon
KR102605798B1 (ko)	2015-02-05	2023-11-23	추가이 세이야쿠 가부시키가이샤	이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2016130969A1 (en)	2015-02-13	2016-08-18	George Robert Pettit	Silstatin compounds
WO2016138160A1 (en)	2015-02-24	2016-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
EP3268038B1 (de)	2015-03-09	2021-05-05	Agensys, Inc.	An flt3-proteine bindende antikörper-wirkstoffkonjugate (adc)
PE20171790A1 (es)	2015-03-23	2017-12-28	Bayer Pharma AG	Anticuerpos anti-ceacam6 y sus usos
WO2016165762A1 (en)	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Drug conjugates comprising antibodies against claudin 18.2
WO2016172485A2 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
CN107810197B (zh)	2015-04-24	2022-10-25	豪夫迈·罗氏有限公司	鉴定包含结合多肽的细菌的方法
EP3288981A1 (de)	2015-05-01	2018-03-07	Genentech, Inc.	Maskierte anti-cd3-antikörper und verfahren zur verwendung
EP3091033A1 (de)	2015-05-06	2016-11-09	Gamamabs Pharma	Anti-human-her3-antikörper und verwendungen davon
US10844111B2 (en)	2015-05-06	2020-11-24	Janssen Biotech, Inc.	Prostate specific membrane antigen binding fibronectin type III domains
HK1248577A1 (zh)	2015-05-11	2018-10-19	F. Hoffmann-La Roche Ag	治疗狼疮性肾炎的组合物和方法
EP3295171A1 (de)	2015-05-12	2018-03-21	INSERM - Institut National de la Santé et de la Recherche Médicale	Verfahren und kits zur markierung, zum nachweis und zur isolierung von foxp3+-regulierenden t-zellen, isolierten populationen von foxp3+-regulierenden t-zellen und verwendungen davon
ES2835866T5 (es)	2015-05-12	2024-12-02	Hoffmann La Roche	Procedimientos terapéuticos y de diagnóstico para el cáncer
WO2016188911A1 (en)	2015-05-22	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
US20180134788A1 (en)	2015-05-26	2018-05-17	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
WO2016189118A1 (en)	2015-05-28	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
ES2789500T5 (es)	2015-05-29	2023-09-20	Hoffmann La Roche	Procedimientos terapéuticos y de diagnóstico para el cáncer
HK1250723A1 (zh)	2015-05-29	2019-01-11	F. Hoffmann-La Roche Ag	人源化抗埃博拉病毒糖蛋白抗体和使用方法
JP2018521019A (ja)	2015-06-08	2018-08-02	ジェネンテック，インコーポレイテッド	抗ｏｘ４０抗体を使用して癌を治療する方法
MX2017015937A (es)	2015-06-08	2018-12-11	Genentech Inc	Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
EP4286511A3 (de)	2015-06-12	2024-03-06	Lentigen Technology, Inc.	Verfahren zur behandlung von krebs mit veränderten t-zellen
CA2989269C (en)	2015-06-15	2020-09-22	Robert Yongxin Zhao	Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
EP3916018A1 (de)	2015-06-16	2021-12-01	Genentech, Inc.	Anti-cd3-antikörper und verfahren zur verwendung
DK3310814T5 (da)	2015-06-16	2024-10-07	Hoffmann La Roche	Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse
US10501545B2 (en)	2015-06-16	2019-12-10	Genentech, Inc.	Anti-CLL-1 antibodies and methods of use
CN107787331B (zh)	2015-06-17	2022-01-11	豪夫迈·罗氏有限公司	抗her2抗体和使用方法
CN107531788B (zh)	2015-06-24	2022-06-21	豪夫迈·罗氏有限公司	对her2和血脑屏障受体特异性的三特异性抗体及使用方法
HUE057952T2 (hu)	2015-06-24	2022-06-28	Hoffmann La Roche	Anti-transzferrin receptor antitestek testreszabott affinitással
EP3313885A1 (de)	2015-06-29	2018-05-02	H. Hoffnabb-La Roche Ag	Typ-ii-cd20-antikörper zur verwendung in der organtransplantation
PL3319993T3 (pl)	2015-07-10	2020-07-27	Genmab A/S	Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
NZ739830A (en)	2015-07-12	2021-12-24	Hangzhou Dac Biotech Co Ltd	Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
UA123398C2 (uk)	2015-08-05	2021-03-31	Янссен Байотек, Інк.	Виділене антагоністичне антитіло, яке специфічно зв'язує cd154, та фармацевтична композиція, яка його містить
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2018028647A1 (en)	2016-08-10	2018-02-15	Legend Biotech Usa Inc.	Chimeric antigen receptors targeting bcma and methods of use thereof
CA3289997A1 (en)	2015-09-20	2026-03-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use
PE20181363A1 (es)	2015-09-23	2018-08-27	Genentech Inc	Variantes optimizadas de anticuerpos anti-vegf
JP6955487B2 (ja)	2015-09-24	2021-10-27	アブビトロ，エルエルシー	Ｈｉｖ抗体組成物および使用方法
PE20181046A1 (es)	2015-09-25	2018-07-03	Genentech Inc	Anticuerpos anti-tigit y metodos de uso
BR112018006251A2 (pt)	2015-09-30	2018-10-16	Janssen Biotech Inc	anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
TWI873952B (zh)	2015-10-02	2025-02-21	瑞士商赫孚孟拉羅股份公司	雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
ES2895034T3 (es)	2015-10-02	2022-02-17	Hoffmann La Roche	Anticuerpos anti-PD1 y procedimientos de uso
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017055404A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific antibodies specific for pd1 and tim3
CA2997809A1 (en)	2015-10-07	2017-04-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
JP6821688B2 (ja)	2015-10-09	2021-01-27	ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉＢｉｏｔｅｃＴｅｃｈｎｏｌｏｇｙ，Ｉｎｃ．	キメラ抗原受容体および使用方法
WO2017060397A1 (en)	2015-10-09	2017-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017064034A1 (en)	2015-10-12	2017-04-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
WO2017066714A1 (en)	2015-10-16	2017-04-20	Compugen Ltd.	Anti-vsig1 antibodies and drug conjugates
WO2017067944A1 (en)	2015-10-19	2017-04-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from triple negative breast cancer
EP3184547A1 (de)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg-antikörper und verfahren zur verwendung
HRP20220064T1 (hr)	2015-10-30	2022-04-15	F. Hoffmann - La Roche Ag	Zglobno modificirani fragmenti protutijela i postupci za pripravu
PE20181326A1 (es)	2015-11-03	2018-08-20	Janssen Biotech Inc	Anticuerpos que se unen especificamente a pd-1 y sus usos
CN118725134A (zh)	2015-11-08	2024-10-01	豪夫迈·罗氏有限公司	筛选多特异性抗体的方法
CN106674327A (zh) *	2015-11-10	2017-05-17	复旦大学	一种Dolastatin 10衍生物、其制备方法及应用
CA3007030A1 (en)	2015-12-07	2017-06-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and psma
EP3178848A1 (de)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
IL313608A (en)	2015-12-09	2024-08-01	Hoffmann La Roche	Antibody against CD20 type II to reduce the formation of antibodies against drugs
WO2017106684A2 (en)	2015-12-17	2017-06-22	Janssen Biotech, Inc.	Antibodies specifically binding hla-dr and their uses
HUE065073T2 (hu)	2015-12-18	2024-04-28	Chugai Pharmaceutical Co Ltd	Anti-C5 antitestek és alkalmazási eljárások
AR107078A1 (es)	2015-12-18	2018-03-21	Chugai Pharmaceutical Co Ltd	Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
KR20180101479A (ko)	2016-01-13	2018-09-12	젠맵 에이/에스	항체 및 그의 약물 접합체를 위한 제제
WO2017132615A1 (en)	2016-01-27	2017-08-03	Sutro Biopharma, Inc.	Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CN108495653A (zh)	2016-01-27	2018-09-04	免疫医疗有限责任公司	用于制备具有定义的糖基化模式抗体的方法
EP3411396A1 (de)	2016-02-04	2018-12-12	Curis, Inc.	Smoothened-mutant und verfahren zur verwendung davon
EP3419655A1 (de)	2016-02-27	2019-01-02	The United States of America, as represented by The Secretary, Department of Health and Human Services	Peptidimpfstoffe mit selbstanordnenden polymernanopartikeln
US20190060473A1 (en)	2016-02-29	2019-02-28	Madrigal Pharmaceuticals, Inc.	Hsp90 inhibitor drug conjugates
JP6821693B2 (ja)	2016-02-29	2021-01-27	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
EP3426693A4 (de)	2016-03-08	2019-11-13	Academia Sinica	Verfahren zur modularen synthese von n-glykanen und anordnungen davon
WO2017161206A1 (en)	2016-03-16	2017-09-21	Halozyme, Inc.	Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CN109641955B (zh)	2016-03-22	2022-07-08	国家医疗保健研究所	人源化抗claudin-1抗体及其用途
CN109843919A (zh)	2016-03-25	2019-06-04	西雅图基因公司	用于制备聚乙二醇化的药物-接头及其中间体的方法
BR112018070948A2 (pt)	2016-04-13	2019-01-29	Orimabs Ltd.	anticorpos anti-psma e utilização dos mesmos
EP3865511A1 (de)	2016-04-14	2021-08-18	F. Hoffmann-La Roche AG	Anti-rspo3-antikörper und verfahren zur verwendung
MX2018012493A (es)	2016-04-15	2019-06-06	Genentech Inc	Métodos para controlar y tratar el cáncer.
SMT202600033T1 (it)	2016-04-15	2026-03-09	Bioatla Inc	Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
KR20190003958A (ko)	2016-04-15	2019-01-10	제넨테크, 인크.	암의 치료 및 모니터링 방법
WO2017191101A1 (en)	2016-05-02	2017-11-09	F. Hoffmann-La Roche Ag	The contorsbody - a single chain target binder
WO2017196847A1 (en)	2016-05-10	2017-11-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
PL3455261T3 (pl)	2016-05-13	2022-12-12	Bioatla, Inc.	Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
EP3465221B1 (de)	2016-05-27	2020-07-22	H. Hoffnabb-La Roche Ag	Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
EP3252078A1 (de)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
WO2018220099A1 (en)	2017-06-02	2018-12-06	F. Hoffmann-La Roche Ag	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2017214182A1 (en)	2016-06-07	2017-12-14	The United States Of America. As Represented By The Secretary, Department Of Health & Human Services	Fully human antibody targeting pdi for cancer immunotherapy
MX2018015285A (es)	2016-06-08	2019-09-18	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
JP2019524651A (ja)	2016-06-08	2019-09-05	アッヴィ・インコーポレイテッド	抗ｃｄ９８抗体及び抗体薬物コンジュゲート
US20200147235A1 (en)	2016-06-08	2020-05-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
AU2017279550A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-B7-H3 antibodies and antibody drug conjugates
WO2017214322A1 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
JP7010854B2 (ja)	2016-06-14	2022-01-26	ゼンコアインコーポレイテッド	二重特異性チェックポイント阻害剤抗体
KR102376582B1 (ko)	2016-06-17	2022-03-18	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
WO2018004338A1 (en)	2016-06-27	2018-01-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
CN109715663B (zh)	2016-06-28	2022-11-25	Xencor股份有限公司	结合生长抑素受体2的异源二聚抗体
US20190233522A1 (en)	2016-07-08	2019-08-01	Genmab A/S	New dosage regimens for antibody drug conjugates based on anti-axl antibodies
JP7062640B2 (ja)	2016-07-29	2022-05-06	ジュノーセラピューティクスインコーポレイテッド	抗ｃｄ１９抗体に対する抗イディオタイプ抗体
EP3494135A1 (de)	2016-08-02	2019-06-12	The United States of America, as represented by The Secretary, Department of Health and Human Services	Gegen glypican-2 (gpc2) gerichtete monoklonale antikörper und verwendung davon
EP3494991A4 (de)	2016-08-05	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
CA3034057A1 (en)	2016-08-22	2018-03-01	CHO Pharma Inc.	Antibodies, binding fragments, and methods of use
CN109790220A (zh)	2016-08-25	2019-05-21	豪夫迈·罗氏有限公司	与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
ES2981703T3 (es)	2016-09-02	2024-10-10	Lentigen Tech Inc	Composiciones y métodos para tratar cáncer con DuoCars
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN109689682B (zh)	2016-09-19	2022-11-29	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
US10517958B2 (en)	2016-10-04	2019-12-31	Zymeworks Inc.	Compositions and methods for the treatment of platinum-drug resistant cancer
CA3038712A1 (en)	2016-10-06	2018-04-12	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
MY203000A (en)	2016-10-14	2024-06-01	Xencor Inc	Il15/il15r� heterodimeric fc-fusion proteins
CA3080270A1 (en)	2016-10-25	2018-05-03	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Monoclonal antibodies binding to the cd160 transmembrane isoform
WO2018081648A2 (en)	2016-10-29	2018-05-03	Genentech, Inc.	Anti-mic antibidies and methods of use
US20190276549A1 (en)	2016-11-01	2019-09-12	Genmab B.V.	Polypeptide variants and uses thereof
KR20220150408A (ko)	2016-11-14	2022-11-10	항저우 디에이씨 바이오테크 씨오, 엘티디	결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
JP7784795B2 (ja)	2016-11-15	2025-12-12	ジェネンテック，インコーポレイテッド	抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
EP3554561B1 (de)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Cd137-bindende fibronectin-typ-iii-domänen
EP3554544A4 (de)	2016-12-16	2020-07-29	Bluefin Biomedicine, Inc.	Anti-cub-haltige protein 1-(cdcp1)-antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
AU2017382883B2 (en)	2016-12-21	2024-07-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies specific for FLT3 and uses thereof
CN110072553B (zh)	2016-12-22	2023-09-15	豪夫迈·罗氏有限公司	在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
EP3565830B1 (de)	2017-01-09	2021-03-10	Lentigen Technology, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs mit anti-mesothelin-immuntherapie
JP6995127B2 (ja)	2017-02-10	2022-02-04	ジェネンテック，インコーポレイテッド	抗トリプターゼ抗体、その組成物、及びその使用
WO2018146253A1 (en)	2017-02-10	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
TW201837467A (zh)	2017-03-01	2018-10-16	美商建南德克公司	用於癌症之診斷及治療方法
KR102648564B1 (ko)	2017-03-24	2024-03-19	씨젠 인크.	글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
CA3057838A1 (en)	2017-03-24	2018-09-27	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd33 immunotherapy
EP3612567B1 (de)	2017-04-19	2024-09-11	Bluefin Biomedicine, Inc.	Anti-vtcn1-antikörper und antikörper-wirkstoff-konjugate
SG11201909395TA (en)	2017-04-27	2019-11-28	Tesaro Inc	Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
WO2018213064A1 (en)	2017-05-19	2018-11-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
AR111963A1 (es)	2017-05-26	2019-09-04	Univ California	Método y moléculas
CR20190550A (es)	2017-06-05	2020-04-05	Janssen Biotech Inc	Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CA3066918A1 (en)	2017-06-12	2018-12-20	Bluefin Biomedicine, Inc.	Anti-il1rap antibodies and antibody drug conjugates
US20210403573A1 (en)	2017-06-22	2021-12-30	INSERM (Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
AU2018290330A1 (en)	2017-06-22	2020-01-02	Mersana Therapeutics, Inc.	Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2019006280A1 (en)	2017-06-30	2019-01-03	Lentigen Technology, Inc.	HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019006472A1 (en)	2017-06-30	2019-01-03	Xencor, Inc.	TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019005208A1 (en)	2017-06-30	2019-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
US20200165347A1 (en)	2017-06-30	2020-05-28	Aslan Pharmaceuticals Pte Ltd	Method of treatment using il-13r antibody
JP7760242B2 (ja)	2017-07-21	2025-10-27	ジェネンテック，インコーポレイテッド	がんの治療法及び診断法
WO2019023316A1 (en)	2017-07-26	2019-01-31	Sutro Biopharma, Inc.	METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
WO2019028051A1 (en)	2017-07-31	2019-02-07	Lentigen Technology, Inc.	COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
JP7250766B2 (ja)	2017-08-25	2023-04-03	ヤンセンバイオテツク，インコーポレーテツド	ＦＣγＲＩＩ結合フィブロネクチンＩＩＩ型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子
ES2960419T3 (es)	2017-09-15	2024-03-04	Lentigen Tech Inc	Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
KR20250035037A (ko)	2017-09-18	2025-03-11	서트로 바이오파마, 인크.	항-엽산 수용체 알파 항체 접합체 및 이의 용도
US10543263B2 (en)	2017-10-16	2020-01-28	Lentigen Technology Inc.	Compositions and methods for treating cancer with anti-CD22 immunotherapy
EP3699590A4 (de)	2017-10-20	2021-09-08	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur messung der internalisierung eines moleküls in eine zelle
WO2019084057A2 (en)	2017-10-24	2019-05-02	Magenta Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
JP7438942B2 (ja)	2017-10-30	2024-02-27	エフ．ホフマン－ラロシュアーゲー	単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
WO2019086394A1 (en)	2017-11-01	2019-05-09	F. Hoffmann-La Roche Ag	The compbody - a multivalent target binder
SG11202003501XA (en)	2017-11-01	2020-05-28	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
MX2020004196A (es)	2017-11-01	2020-11-09	Hoffmann La Roche	Trifab-contorsbody.
EP3703711A4 (de)	2017-11-03	2021-01-13	Lentigen Technology, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs mit anti-ror1-immuntherapie
TW201923089A (zh)	2017-11-06	2019-06-16	美商建南德克公司	癌症之診斷及治療方法
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja)	2017-11-08	2021-01-28	ゼンコアインコーポレイテッド	新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
WO2019094709A1 (en)	2017-11-09	2019-05-16	Pettit George R	Betulastatin compounds
EP4640703A3 (de)	2017-11-14	2026-04-08	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s-antikörper und verfahren zur verwendung
GB201719646D0 (en)	2017-11-27	2018-01-10	Bivictrix Therapeutics Ltd	Therapy
CN119857155A (zh)	2017-11-29	2025-04-22	海德堡医药研究有限责任公司	用于耗尽cd5+细胞的组合物和方法
WO2019105972A1 (en)	2017-11-30	2019-06-06	Bayer Aktiengesellschaft	Ildr2 antagonists and combinations thereof
EP3498293A1 (de)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
IL275426B2 (en)	2017-12-19	2025-03-01	Xencor Inc	Engineered il-2 fc fusion proteins
AU2018388997B2 (en)	2017-12-20	2025-04-03	Lentigen Technology, Inc.	Compositions and methods for treating HIV/AIDS with immunotherapy
JP7314146B2 (ja)	2017-12-28	2023-07-25	中外製薬株式会社	細胞傷害誘導治療剤
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3740505A1 (de)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
IL325995A (en)	2018-02-08	2026-03-01	Genentech Inc	Bispecific antigen binding molecules and methods of use
CN111836831A (zh)	2018-02-26	2020-10-27	豪夫迈·罗氏有限公司	用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
EP3765517A1 (de)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
CN112119090B (zh)	2018-03-15	2023-01-13	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
CA3096052A1 (en)	2018-04-04	2019-10-10	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
CR20250325A (es)	2018-04-13	2025-08-29	Genentech Inc	Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
SG11202010163QA (en)	2018-04-18	2020-11-27	Xencor Inc	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (de)	2018-04-18	2021-02-24	Xencor, Inc.	Auf tim-3 abzielende heterodimere fusionsproteine mit il-15-/il-15ra-fc-fusionsproteinen und tim-3-antigen-bindenden domänen
CA3099421C (en)	2018-05-04	2025-05-06	Tagworks Pharmaceuticals B.V.	COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
AU2019262520B2 (en)	2018-05-04	2025-07-10	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
UA129352C2 (uk)	2018-05-07	2025-03-26	Генмаб А/С	Способи лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора та лікарського засобу
TW202506732A (zh)	2018-05-07	2025-02-16	丹麥商珍美寶股份有限公司	使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
AU2019271148B9 (en)	2018-05-14	2025-05-29	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable interleukin 12 polypeptides and methods of use thereof
PE20211916A1 (es)	2018-05-24	2021-09-28	Janssen Biotech Inc	Agentes aglutinantes del psma y usos de estos
WO2020006347A1 (en)	2018-06-29	2020-01-02	Boehringer Ingelheim International Gmbh	Anti-cd40 antibodies for use in treating autoimmune disease
TW202519260A (zh)	2018-07-02	2025-05-16	美商安進公司	抗steap1抗原結合蛋白
CA3105448A1 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
EP3820909B1 (de)	2018-07-11	2023-03-01	The United States of America, as represented by the Secretary, Department of Health and Human Services	Monoklonaler antikörper zum nachweis des antiviralen arzneimittels emtricitabin (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidin)
US11939377B2 (en)	2018-07-12	2024-03-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Affinity matured CD22-specific monoclonal antibody and uses thereof
CA3107383A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
EP3833684A1 (de)	2018-08-08	2021-06-16	The United States of America, as represented by the Secretary, Department of Health and Human Services	Gegen glypican-2 gerichtete, hochaffine monoklonale antikörper und verwendungen davon
KR102259473B1 (ko)	2018-08-10	2021-06-02	추가이 세이야쿠 가부시키가이샤	항cd137 항원 결합 분자 및 그의 사용
EP3850013A4 (de)	2018-09-10	2022-10-05	Nanjing Legend Biotech Co., Ltd.	Einzeldomänenantikörper gegen cll1 und verwendungen davon
JP2022500454A (ja)	2018-09-17	2022-01-04	ストロバイオファーマインコーポレーテッド	抗葉酸受容体抗体コンジュゲートによる併用療法
AU2019342099A1 (en)	2018-09-19	2021-04-08	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
EP3853251A1 (de)	2018-09-19	2021-07-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und pharmazeutische zusammensetzung zur behandlung von krebserkrankungen mit resistenz gegen immun-checkpoint-therapie
EP3853254A1 (de)	2018-09-20	2021-07-28	Lentigen Technology, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd123-immuntherapie
EP3626265A1 (de)	2018-09-21	2020-03-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-human-cd45rc-antikörper und verwendungen davon
JP7546554B2 (ja)	2018-09-26	2024-09-06	レンティジェン・テクノロジー・インコーポレイテッド	抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
US20220002370A1 (en)	2018-09-27	2022-01-06	Xilio Development, Inc.	Masked cytokine polypeptides
AU2019355971B2 (en)	2018-10-03	2025-05-08	Xencor, Inc.	IL-12 heterodimeric Fc-fusion proteins
EP3867646A1 (de)	2018-10-18	2021-08-25	F. Hoffmann-La Roche AG	Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
CN113365664A (zh)	2018-10-29	2021-09-07	梅尔莎纳医疗公司	具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
MY195550A (en)	2018-10-29	2023-01-31	Hoffmann La Roche	Antibody Formulation
TWI844571B (zh)	2018-10-30	2024-06-11	丹麥商珍美寶股份有限公司	使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2020094609A1 (en)	2018-11-06	2020-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
CN119592592A (zh)	2018-11-30	2025-03-11	莱蒂恩技术公司	用于用抗cd38免疫治疗来治疗癌症的组合物和方法
AU2019392090A1 (en)	2018-12-03	2021-06-17	Agensys, Inc.	Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
BR112021010908A2 (pt)	2018-12-06	2021-08-31	Genentech, Inc.	Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
JP2022513198A (ja)	2018-12-10	2022-02-07	ジェネンテック，インコーポレイテッド	Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
EP3894543A1 (de)	2018-12-14	2021-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Isolierte humane mhc-abgeleitete peptide und verwendungen davon zur stimulierung und aktivierung der suppressiven funktion von cd8cd45rc + cd45rc low tregs
EP3898699A1 (de)	2018-12-19	2021-10-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur behandlung von krebs durch immunmodulation unter verwendung von antikörpern gegen cathespin-d
AR117453A1 (es)	2018-12-20	2021-08-04	Genentech Inc	Fc de anticuerpos modificados y métodos para utilizarlas
WO2020127968A1 (en)	2018-12-20	2020-06-25	Marino Stephen F	Protein-drug conjugate comprising a monomeric form of proteinase 3
CA3122773A1 (en)	2018-12-26	2020-07-02	Xilio Development, Inc.	Anti-ctla4 antibodies and methods of use thereof
CA3125484A1 (en)	2019-01-08	2020-07-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cross-species single domain antibodies targeting mesothelin for treating solid tumors
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
US12122843B2 (en)	2019-01-22	2024-10-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-1 and methods of use
BR112021014276A2 (pt)	2019-01-22	2021-09-28	Genentech, Inc.	Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
WO2020153467A1 (ja)	2019-01-24	2020-07-30	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
SG11202107976SA (en)	2019-01-29	2021-08-30	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CN119039441A (zh)	2019-02-21	2024-11-29	马伦戈治疗公司	与nkp30结合的抗体分子及其用途
GB2599228B (en)	2019-02-21	2024-02-07	Marengo Therapeutics Inc	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020176748A1 (en)	2019-02-27	2020-09-03	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
CA3132185A1 (en)	2019-03-01	2020-09-10	Xencor, Inc.	Heterodimeric antibodies that bind enpp3 and cd3
CN113924103B (zh)	2019-03-06	2025-02-14	莱蒂恩技术公司	用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
EP3938403A1 (de)	2019-03-14	2022-01-19	F. Hoffmann-La Roche AG	Behandlung von krebs mit her2xcd3-bispezifischen antikörpern in kombination mit anti-her2-mab
US11591395B2 (en)	2019-04-19	2023-02-28	Janssen Biotech, Inc.	Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
BR112021020867A2 (pt)	2019-04-19	2022-01-04	Genentech Inc	Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
WO2020227105A1 (en)	2019-05-03	2020-11-12	Sutro Biopharma, Inc.	Anti-bcma antibody conjugates
EP3969035A4 (de)	2019-05-14	2023-06-21	Werewolf Therapeutics, Inc.	Trennungseinheiten und verfahren und ihre verwendung
AU2020275415B2 (en)	2019-05-14	2026-01-15	Genentech, Inc.	Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
EP4696320A2 (de)	2019-05-15	2026-02-18	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s anitkörper
CA3140102A1 (en)	2019-05-30	2020-12-03	Dina SCHNEIDER	Compositions and methods for treating cancer with anti-bcma immunotherapy
DK3983363T3 (da)	2019-06-17	2024-06-24	Tagworks Pharmaceuticals B V	Forbindelser til hurtig og effektiv klikfrigivelse
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
WO2021003297A1 (en)	2019-07-02	2021-01-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind egfrviii and their use
MX2022000111A (es)	2019-07-10	2022-02-10	Chugai Pharmaceutical Co Ltd	Moleculas de union a claudina-6 y usos de las mismas.
WO2021010326A1 (ja)	2019-07-12	2021-01-21	中外製薬株式会社	抗変異型ｆｇｆｒ３抗体およびその使用
BR112022001368A2 (pt)	2019-07-26	2022-05-24	Janssen Biotech Inc	Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CA3149494A1 (en)	2019-08-12	2021-02-18	Purinomia Biotech, Inc.	Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CN114258400A (zh)	2019-08-15	2022-03-29	詹森生物科技公司	用于改进的单链可变片段的材料和方法
JP2022548978A (ja)	2019-09-27	2022-11-22	ジェネンテック，インコーポレイテッド	薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
WO2021064184A1 (en)	2019-10-04	2021-04-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
WO2021076196A1 (en)	2019-10-18	2021-04-22	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3156761A1 (en)	2019-10-22	2021-04-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
EP3812008A1 (de)	2019-10-23	2021-04-28	Gamamabs Pharma	Amh-kompetitiver antagonistischer antikörper
US11802151B2 (en)	2019-11-04	2023-10-31	Code Biotherapeutics, Inc.	Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
KR20220092580A (ko)	2019-11-06	2022-07-01	제넨테크, 인크.	혈액암의 치료를 위한 진단과 치료 방법
TW202132343A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TW202131954A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
MX2022005666A (es)	2019-11-14	2022-10-07	Werewolf Therapeutics Inc	Polipeptidos de citocina activables y metodos de uso de los mismos.
EP4069742A1 (de)	2019-12-06	2022-10-12	Juno Therapeutics, Inc.	Anti-idiotypische antikörper gegen gprc5d-gerichtete bindungsdomänen und verwandte zusammensetzungen und verfahren
CN115916817A (zh)	2019-12-06	2023-04-04	朱诺治疗学股份有限公司	针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
WO2021118968A1 (en)	2019-12-12	2021-06-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-drug conjugates specific for cd276 and uses thereof
WO2021119505A1 (en)	2019-12-13	2021-06-17	Genentech, Inc.	Anti-ly6g6d antibodies and methods of use
UA128549C2 (uk)	2019-12-27	2024-08-07	Чугаі Сейяку Кабусікі Кайся	Антитіло до ctla-4 та його застосування
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
AU2020416273A1 (en)	2020-01-03	2022-07-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
US20230095053A1 (en)	2020-03-03	2023-03-30	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
PE20230252A1 (es)	2020-03-13	2023-02-07	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos de estos
JP2023517660A (ja)	2020-03-13	2023-04-26	ヤンセンバイオテツク，インコーポレーテツド	シグレック３／ｃｄ３３に結合させるための材料及び方法
CN117551194A (zh)	2020-03-19	2024-02-13	基因泰克公司	同种型选择性抗TGF-β抗体及使用方法
WO2021202959A1 (en)	2020-04-03	2021-10-07	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
CN115916822A (zh)	2020-04-24	2023-04-04	基因泰克公司	使用抗CD79b免疫缀合物的方法
EP4143345A1 (de)	2020-04-28	2023-03-08	Genentech, Inc.	Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4153628A1 (de)	2020-05-20	2023-03-29	Institut Curie	Einzeldomänenantikörper und deren verwendung in krebstherapien
CN116249714A (zh)	2020-05-27	2023-06-09	詹森生物科技公司	包含cd3抗原结合结构域的蛋白质及其用途
JP2023529206A (ja)	2020-06-12	2023-07-07	ジェネンテック，インコーポレイテッド	がん免疫療法のための方法及び組成物
KR20230024368A (ko)	2020-06-18	2023-02-20	제넨테크, 인크.	항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
US11497770B2 (en)	2020-06-22	2022-11-15	Lentigen Technology, Inc.	Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
EP4171652A1 (de)	2020-06-29	2023-05-03	Genmab A/S	Antikörper-wirkstoff-konjugate gegen den gewebefaktor und deren verwendung bei der behandlung von krebs
EP4175664A2 (de)	2020-07-06	2023-05-10	Janssen Biotech, Inc.	Prostata-neoantigene und ihre verwendungen
TW202204895A (zh)	2020-07-13	2022-02-01	美商建南德克公司	預測多肽免疫性的基於細胞之方法
JP7846667B2 (ja)	2020-07-16	2026-04-15	レジェンドバイオテックアイルランドリミテッド	Ｃｄ２０結合分子及びその使用
EP4190801A4 (de)	2020-07-29	2024-10-02	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur messung der pharmakokinetik eines mit einer nichtradioaktiven substanz markierten arzneimittels
KR20230041819A (ko)	2020-07-29	2023-03-24	얀센 바이오테크 인코포레이티드	Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
EP4189071A1 (de)	2020-08-03	2023-06-07	Institut National de la Santé et de la Recherche Médicale (INSERM)	Population von treg-zellen, die funktionell mit einer regulatorischen aktivität behaftet sind, und ihre verwendung zur adoptiven therapie
EP4192868A1 (de)	2020-08-05	2023-06-14	Juno Therapeutics, Inc.	Antiidiotypische antikörper gegen ror1-gerichtete bindungsdomänen und zugehörige zusammensetzungen und verfahren
BR112023002123A2 (pt)	2020-08-07	2023-03-07	Genentech Inc	Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo
EP4192942A1 (de)	2020-08-07	2023-06-14	Genentech, Inc.	Verfahren auf t-zellen-basis zur vorhersage der immunogenität von polypeptiden
CN112062855B (zh)	2020-08-26	2024-08-30	北京天诺健成医药科技有限公司	一种含有衔接器的药物治疗剂的开发和应用
EP4213939A1 (de)	2020-09-21	2023-07-26	Boehringer Ingelheim International GmbH	Verwendung von anti-cd40-antikörpern zur behandlung von entzündlichen erkrankungen
CN116406291A (zh)	2020-10-05	2023-07-07	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
TW202231292A (zh)	2020-10-13	2022-08-16	美商健生生物科技公司	用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
WO2022079270A1 (en)	2020-10-16	2022-04-21	Université D'aix-Marseille	Anti-gpc4 single domain antibodies
CA3199319A1 (en)	2020-10-22	2022-04-28	Janssen Biotech, Inc.	Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
US20230391852A1 (en)	2020-10-26	2023-12-07	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting sars coronavirus spike protein and uses thereof
JP7716473B2 (ja)	2020-11-04	2025-07-31	ジェネンテック，インコーポレイテッド	抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
AU2021374594B2 (en)	2020-11-04	2026-03-05	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
TWI874719B (zh)	2020-11-04	2025-03-01	美商建南德克公司	用抗cd20/抗cd3雙特異性抗體進行治療之給藥
AU2021372997A1 (en)	2020-11-05	2023-06-22	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
CN114524878B (zh)	2020-11-23	2024-08-02	康诺亚生物医药科技（成都）有限公司	一种双特异性抗体及其用途
WO2022115865A2 (en)	2020-11-25	2022-06-02	Xilio Development, Inc.	Tumor-specific cleavable linkers
CN114573703A (zh)	2020-12-02	2022-06-03	康诺亚生物医药科技（成都）有限公司	一种t细胞衔接器治疗剂的开发和应用
CN114573702A (zh)	2020-12-02	2022-06-03	康诺亚生物医药科技（成都）有限公司	一种新型肿瘤衔接器治疗药物的开发和应用
WO2022116877A1 (en)	2020-12-02	2022-06-09	Shanghai Henlius Biotech, Inc.	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
MX2023007133A (es)	2020-12-17	2023-06-27	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de estos.
GB202020572D0 (en)	2020-12-23	2021-02-03	Bivictrix Therapeutics Ltd	Novel methods of therapy
GB202020573D0 (en)	2020-12-23	2021-02-03	Bivictrix Therapeutics Ltd	Novel methods of therapy
CN114685657B (zh)	2020-12-31	2024-08-16	康诺亚生物医药科技（成都）有限公司	一种功能增强型抗体阻断剂的开发及其应用
US20240317890A1 (en)	2021-01-14	2024-09-26	Institut Curie	Her2 single domain antibodies variants and cars thereof
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
EP4284838A2 (de)	2021-01-28	2023-12-06	Janssen Biotech, Inc.	Psma-bindende proteine und verwendungen davon
KR20230146032A (ko)	2021-02-15	2023-10-18	다케다 야쿠힌 고교 가부시키가이샤	Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
US20250161478A1 (en)	2021-02-16	2025-05-22	Glykos Finland Oy	Linker payloads and conjugates thereof
CA3209364A1 (en)	2021-03-01	2022-09-09	Jennifer O'neil	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301467A1 (de)	2021-03-01	2024-01-10	Xilio Development, Inc.	Kombination von ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
US11739144B2 (en)	2021-03-09	2023-08-29	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (de)	2021-03-10	2024-01-17	Xencor, Inc.	Cd3 und gpc3 bindende heterodimere antikörper
WO2022200303A1 (en)	2021-03-23	2022-09-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of t cell-lymphomas
CN117098781A (zh)	2021-03-24	2023-11-21	詹森生物科技公司	靶向cd22和cd79b的抗体
US12084501B2 (en)	2021-03-24	2024-09-10	Janssen Biotech, Inc.	Proteins comprising CD3 antigen binding domains and uses thereof
CN117396504A (zh)	2021-03-30	2024-01-12	拜耳公司	抗Sema3A抗体及其用途
EP4320153A1 (de)	2021-04-09	2024-02-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur behandlung von anaplastischem grosszelligem lymphom
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
WO2022232612A1 (en)	2021-04-29	2022-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lassa virus-specific nanobodies and methods of their use
WO2022232488A1 (en)	2021-04-30	2022-11-03	Celgene Corporation	Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
CA3213632A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202244059A (zh)	2021-04-30	2022-11-16	瑞士商赫孚孟拉羅股份公司	用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
IL308351A (en)	2021-05-12	2024-01-01	Genentech Inc	Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
US20250076283A1 (en)	2021-05-19	2025-03-06	Chugai Seiyaku Kabushiki Kaisha	Method for predicting in vivo pharmacokinetics of molecule
CN117396513A (zh)	2021-05-28	2024-01-12	葛兰素史密斯克莱知识产权发展有限公司	治疗癌症的联合疗法
TW202306994A (zh)	2021-06-04	2023-02-16	日商中外製藥股份有限公司	抗ddr2抗體及其用途
US20240270851A1 (en)	2021-06-09	2024-08-15	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting pd-l1 for treating solid tumors
TWI879694B (zh)	2021-06-25	2025-04-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
AR126220A1 (es)	2021-06-25	2023-09-27	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-ctla-4
TW202317190A (zh)	2021-06-29	2023-05-01	美商思進公司	以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法
US11807685B2 (en)	2021-08-05	2023-11-07	The Uab Research Foundation	Anti-CD47 antibody and uses thereof
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
AU2022333321A1 (en)	2021-08-27	2024-04-11	Janssen Biotech, Inc.	Anti-psma antibodies and uses thereof
CN118043352A (zh)	2021-09-02	2024-05-14	德国癌症研究中心公共法律基金会	副作用减少的抗cecam6抗体
CN118119409A (zh)	2021-09-03	2024-05-31	东丽株式会社	癌的治疗和/或预防用药物组合物
US20250327057A1 (en)	2021-09-06	2025-10-23	Veraxa Biotech Gmbh	Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
PL4401842T3 (pl)	2021-09-16	2025-11-24	Aboleris Pharma	Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
US20250019455A1 (en)	2021-09-24	2025-01-16	Pharmaceutica Nv	Proteins comprising cd20 binding domains, and uses thereof
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CA3233953A1 (en)	2021-10-05	2023-04-13	Matthew Bruce	Combination therapies for treating cancer
EP4413998A4 (de)	2021-10-08	2026-02-25	Chugai Pharmaceutical Co Ltd	Verfahren zur herstellung einer vorgefüllten spritzenformulierung
EP4426727A2 (de)	2021-11-03	2024-09-11	Hangzhou Dac Biotech Co., Ltd.	Spezifische konjugation eines antikörpers
TW202337494A (zh)	2021-11-16	2023-10-01	美商建南德克公司	用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
WO2023089587A1 (en)	2021-11-22	2023-05-25	Janssen Biotech, Inc.	Compositions comprising enhanced multispecific binding agents for an immune response
WO2023094525A1 (en)	2021-11-25	2023-06-01	Veraxa Biotech Gmbh	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
DK4186529T3 (da)	2021-11-25	2025-08-25	Veraxa Biotech Gmbh	Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
US20250135011A1 (en)	2021-12-08	2025-05-01	European Molecular Biology Laboratory	Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
US20250051440A1 (en)	2021-12-14	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
KR20240116755A (ko)	2021-12-17	2024-07-30	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
KR20240122784A (ko)	2021-12-17	2024-08-13	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체 및 사용 방법
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
WO2023144303A1 (en)	2022-01-31	2023-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd38 as a biomarker and biotarget in t-cell lymphomas
US20250114489A1 (en)	2022-02-15	2025-04-10	Tagworks Pharmaceuticals B.V.	Masked il12 protein
GB202202171D0 (en)	2022-02-17	2022-04-06	Bivictrix Ltd	Novel methods of therapy
GB202202170D0 (en)	2022-02-17	2022-04-06	Bivictrix Ltd	Novel methods of therapy
US20230338424A1 (en)	2022-03-02	2023-10-26	Lentigen Technology, Inc.	Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US11590169B1 (en)	2022-03-02	2023-02-28	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-CD123 immunotherapy
MX2024011468A (es)	2022-03-23	2024-09-25	Hoffmann La Roche	Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
CA3245762A1 (en)	2022-03-25	2023-09-28	Shanghai Henlius Biologics Co., Ltd.	ANTI-MSLN ANTIBODIES AND METHODS OF USE
IL315770A (en)	2022-04-01	2024-11-01	Genentech Inc	Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
WO2023198648A1 (en)	2022-04-11	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of t-cell malignancies
WO2023201299A1 (en)	2022-04-13	2023-10-19	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023198727A1 (en)	2022-04-13	2023-10-19	F. Hoffmann-La Roche Ag	Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023198874A1 (en)	2022-04-15	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of t cell-lymphomas
IL316289A (en)	2022-04-29	2024-12-01	Purinomia Biotech Inc	Methods and compositions for treating diseases and disorders driven by eosinophils
US20230346862A1 (en)	2022-05-02	2023-11-02	Athanor Biosciences, Inc.	Cancer eradicating - bio-nanoparticles (ce-bnp)
WO2023213960A1 (en)	2022-05-06	2023-11-09	Genmab A/S	Methods of treating cancer with anti-tissue factor antibody-drug conjugates
JP2025517650A (ja)	2022-05-11	2025-06-10	ジェネンテック，インコーポレイテッド	抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
KR20250022049A (ko)	2022-06-07	2025-02-14	제넨테크, 인크.	항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
CA3259758A1 (en)	2022-06-30	2024-01-04	Sutro Biopharma, Inc.	Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates
WO2024003310A1 (en)	2022-06-30	2024-01-04	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of acute lymphoblastic leukemia
AU2023305619A1 (en)	2022-07-13	2025-01-23	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3261603A1 (en)	2022-07-15	2024-01-18	Pheon Therapeutics Ltd	ANTIBODY-DRUG CONJUGATES
KR20250040020A (ko)	2022-07-19	2025-03-21	제넨테크, 인크.	항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
TW202417504A (zh)	2022-07-22	2024-05-01	美商建南德克公司	抗ｓｔｅａｐ１抗原結合分子及其用途
JP2025526336A (ja)	2022-07-22	2025-08-13	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
CN119923410A (zh)	2022-07-28	2025-05-02	莱蒂恩技术公司	用于治疗实体瘤的嵌合抗原受体治疗
WO2024023283A1 (en)	2022-07-29	2024-02-01	Institut National de la Santé et de la Recherche Médicale	Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
WO2024044743A1 (en)	2022-08-26	2024-02-29	Lentigen Technology, Inc.	Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
EP4581366A1 (de)	2022-09-01	2025-07-09	Genentech, Inc.	Therapeutische und diagnostische verfahren für blasenkrebs
WO2024080872A1 (en)	2022-10-12	2024-04-18	Tagworks Pharmaceuticals B.V.	Strained bicyclononenes
JP2025536268A (ja)	2022-10-12	2025-11-05	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｃｄ８１
KR20250093336A (ko)	2022-10-25	2025-06-24	제넨테크, 인크.	다발성 골수종에 대한 치료 및 진단 방법
WO2024102948A1 (en)	2022-11-11	2024-05-16	Celgene Corporation	Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
KR20250135354A (ko)	2022-12-13	2025-09-12	주노 쎄러퓨티크스 인코퍼레이티드	Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
WO2024153789A1 (en)	2023-01-20	2024-07-25	Basf Se	Stabilized biopolymer composition, their manufacture and use
JP2026506554A (ja)	2023-02-06	2026-02-25	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	多重塩基編集による遺伝子改変造血幹細胞の濃縮
WO2024170543A1 (en)	2023-02-14	2024-08-22	Institut National de la Santé et de la Recherche Médicale	Anti-cd44 antibodies and uses thereof
WO2024191293A1 (en)	2023-03-10	2024-09-19	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene with improved t-linker
CN121311250A (zh)	2023-03-22	2026-01-09	信立泰生物医药公司	抗5t4抗原结合结构域、抗体-药物缀合物及其使用方法
WO2024218345A1 (en)	2023-04-21	2024-10-24	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
AU2024270495A1 (en)	2023-05-05	2025-10-09	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4713371A1 (de)	2023-05-17	2026-03-25	Institut National de la Santé et de la Recherche Médicale	Anti-cathepsin-d-antikörper
KR20260021689A (ko)	2023-06-08	2026-02-13	제넨테크, 인크.	림프종 진단 및 치료 방법을 위한 대식세포 시그니처
WO2025014896A1 (en)	2023-07-07	2025-01-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Humanized 40h3 antibody
AU2024295016A1 (en)	2023-07-20	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
KR20260046464A (ko)	2023-07-27	2026-04-07	베락사 바이오테크 게엠베하	친수성 트랜스-시클로옥텐(hyTCO) 화합물, 이를 포함하는 구조체 및 접합체
WO2025027529A1 (en)	2023-07-31	2025-02-06	Advesya	Anti-il-1rap antibody drug conjugates and methods of use thereof
GB202312575D0 (en)	2023-08-17	2023-10-04	Bivictrix Ltd	Bispecific antibodies
GB202312576D0 (en)	2023-08-17	2023-10-04	Bivictrix Ltd	A compound comprising a first and second antibody or antigen-binding fragment and methods of conjugating the same
WO2025056807A1 (en)	2023-09-15	2025-03-20	Basf Se	Stabilized biopolymer composition, their manufacture and use
GB202314424D0 (en)	2023-09-20	2023-11-01	Cambridge Entpr Ltd	A conjugate
AU2024358957A1 (en)	2023-10-13	2026-04-02	Sutro Biopharma, Inc.	Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025120015A1 (en)	2023-12-06	2025-06-12	Institut National de la Santé et de la Recherche Médicale	Cd5 targeting antibodies with depleting and t or b-cell activation effects
TW202530255A (zh)	2023-12-15	2025-08-01	法商亞維西亞有限公司	抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025171238A1 (en)	2024-02-07	2025-08-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
GB202402046D0 (en)	2024-02-14	2024-03-27	Bivictrix Ltd	Therapeutic antibodies
GB202402048D0 (en)	2024-02-14	2024-03-27	Bivictrix Ltd	Therapeutic antibodies
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
EP4624494A1 (de)	2024-03-29	2025-10-01	Institut Curie	Her2-einzeldomänenantikörper und verwendungen davon
WO2025223455A1 (en)	2024-04-24	2025-10-30	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anti-ptk7/b7h3 antibodies and uses thereof
WO2025238052A1 (en)	2024-05-15	2025-11-20	Institut National de la Santé et de la Recherche Médicale	Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
WO2025250825A1 (en)	2024-05-30	2025-12-04	Sutro Biopharma, Inc.	Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025248500A1 (en)	2024-05-31	2025-12-04	Janssen Biotech, Inc.	Antibody drug conjugates that target enpp3
US20260000765A1 (en)	2024-06-27	2026-01-01	Lentigen Technology, Inc.	CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026043823A2 (en)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026043376A1 (en)	2024-08-22	2026-02-26	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene formulations
WO2026077659A1 (en)	2024-09-17	2026-04-16	Institut National de la Santé et de la Recherche Médicale	Enrichment of genetically modified hematopoietic stem cells through epigenome editing
WO2026061986A1 (en)	2024-09-17	2026-03-26	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
WO2026078060A1 (en)	2024-10-08	2026-04-16	Basf Se	Tocopherol alkoxylates for biopolymer stabilization
WO2026080697A1 (en)	2024-10-09	2026-04-16	Sutro Biopharma, Inc.	Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4978744A (en) *	1989-01-27	1990-12-18	Arizona Board Of Regents	Synthesis of dolastatin 10

1993
- 1993-01-26 US US08/009,296 patent/US5780588A/en not_active Expired - Fee Related
1994
- 1994-01-20 JP JP6032795A patent/JPH08119990A/ja active Pending
- 1994-01-24 DE DE69407322T patent/DE69407322T2/de not_active Expired - Fee Related
- 1994-01-24 EP EP94300495A patent/EP0612762B1/de not_active Expired - Lifetime
- 1994-01-24 AT AT94300495T patent/ATE161270T1/de not_active IP Right Cessation
- 1994-01-25 CA CA002114156A patent/CA2114156C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2114156A1 (en)	1994-07-27
US5780588A (en)	1998-07-14
CA2114156C (en)	2001-01-02
JPH08119990A (ja)	1996-05-14
EP0612762B1 (de)	1997-12-17
DE69407322T2 (de)	1998-06-04
EP0612762A1 (de)	1994-08-31
DE69407322D1 (de)	1998-01-29

Legal Events

Date	Code	Title	Description
1998-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE161270T1 (de)	1998-01-15	Aufklärung und synthese von ausgewählten pentapeptiden
EP0787009A4 (de)	1999-09-22	Krebs hemmende peptide
EP0473084A3 (en)	1992-04-29	Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides
ATE194828T1 (de)	2000-08-15	Entzündungshemmendes und analgetisches äusserliches pflaster-präparat
DE69627704T2 (de)	2004-01-29	Protegrine
ATE209215T1 (de)	2001-12-15	Protegrine
FI973879A0 (fi)	1997-10-03	Tienyl-,furyl-,pyrrolyl- och bifenylsulfonamider och derivat daerav sommodulerar endotelinativiteten
NO170280C (no)	1992-09-30	Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
ATE197038T1 (de)	2000-11-15	N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen
DE69428142D1 (de)	2001-10-11	Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
BR0309558A (pt)	2005-03-01	Derivados de quinazolina e medicamentos
BR9812238A (pt)	2000-07-18	Composto, uso deste, processo para a preparação do mesmo, formulação farmacêutica, e, processos para o tratamento de distúrbios do sistema nervoso central e/ou incontinência urinária, ou vasoespasmo, ou para controle de crescimento de tumores, e para o tratamento de distúrbios mediados por 5-hidroxitriptamina
RU94044534A (ru)	1996-10-27	Амино-производные тиазола, способы их получения и содержащие их фармацевтические композиции
PT649846E (pt)	2002-06-28	Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos
ES8103027A1 (es)	1981-02-16	Un procedimiento para la preparacion de un polipeptido
RU93027054A (ru)	1995-11-20	Мазь противовоспалительная
RU94022277A (ru)	1996-04-20	Новые 19-норстероиды, имеющие в положении 11 - бета феноксиалкилсульфонамидную или феноксиалкилсульфонилкарбамидную цепь, метод и промежуточные продукты их получения, и содержащая их фармацевтическая композиция
DE68924804D1 (de)	1995-12-21	Polypeptid mit sich wiederholenden zelladhäsiven Hauptsequenzen.
ES2133295T3 (es)	1999-09-16	Peptidos ciclicos y su uso.
ATE114154T1 (de)	1994-12-15	Thienotriazolodiazepine und ihre pharmazeutische verwendung.
ATE356814T1 (de)	2007-04-15	Heterozyclische verbindungen, ihr herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
DK0529410T3 (da)	1998-05-11	Antibiotikum GE 2270 faktor C2a
RU94046464A (ru)	1996-09-10	Новые биологически активные n-ацилпролилдипептиды, обладающие антиамнезийным, антигипоксийным и анорексигенным эффектами, способ их получения и содержащие их фармацевтический состав и лекарство
RU95109891A (ru)	1997-02-10	19,11-перекрытые мостиками 4-эстрены, способ их получения, содержащая их фармацевтическая композиция и промежуточные соединения для их получения
DE69224613D1 (de)	1998-04-09	Peptide, Herstellung und deren Verwendung